The aim of this study wasto determine the effects of advanced chronic kidney disease (CKD) on earlyand late outcomes after transcatheter aortic valve implantation (TAVI), and to evaluate the predictive factors of poorer outcomes in such patients.
Introduction
Chronic kidney disease (CKD) is a rapidly growing worldwide public health problem with considerable economic and social repercussions. 1 It is well known that CKD modifies the natural history of cardiovascular diseases, and the presence of CKD has been associated with a much poorer prognosis in patients diagnosed with heart failure, coronary artery or valvular heart disease, and in those undergoing cardiac interventions. 2 The presence of CKD increases the risk of early and late mortality in patients with aortic stenosis undergoing surgical aortic valve replacement (SAVR), and the prognosis can be dismal in those with end-stage kidney disease. 3 -7 Transcatheter aortic valve implantation (TAVI) has been consolidated as a valid alternative to SAVR in those patients considered at high or prohibitive surgical risk. 8 Patients undergoing TAVI nowadays are thus frequently very old and have a high prevalence of non-cardiac comorbidities, including CKD, which accounts for 30-50% of TAVI candidates. 8 Several studies have shown that the presence of CKD is associated with poorer outcomes following TAVI, and early and late mortality rates increase with a greater severity of kidney dysfunction. 8 -12 The mortality rate associated with severe CKD has been .30% at 1-year follow-up after TAVI, and this raises doubts about the appropriateness of offering this treatment to patients with aortic stenosis and severe CKD. Indeed, patients with end-stage kidney disease, especially those on dialysis therapy, have been excluded from many TAVI studies 9, 11, 12 including the PARTNER I and II trials (clinicaltrials.gov.= NCT00530894; clinicaltrial.gov.= NCT01314313) and the pivotal US trial for the CoreValve system (clinicaltrials.gov.= NCT01240902), which may make it even more difficult to draw meaningful conclusions for the clinical decision-making process in such patients. Moreover, no data exist on the factors determining poorer outcomes in patients with advanced CKD undergoing TAVI, and a better knowledge of the prognostic markers among such patients would therefore be of major importance in improving both patient selection and management. Finally, the presence of end stage renal disease has been correlated with enhanced aortic valve calcification and valve disease progression, and cases of very rapid deterioration of surgical aortic bioprostheses have been reported in such patients; 13 -15 however, few data exist on the effects of advanced CKD on valve haemodynamics following TAVI. The objectives of this study were therefore (i) to determine the effects of advanced CKD on early and late outcomes, functional status, and valve haemodynamics following TAVI, and (ii) to evaluate the predictive factors of poorer outcomes in patients with advanced CKD undergoing TAVI.
Methods
A total of 2075 consecutive patients who underwent TAVI in nine centres between January 2005 and June 2012 were included. Patients' comorbidities were defined according to the STS risk score definitions. Patient selection, approach and the type of transcatheter valve used during the TAVI procedures were determined by the heart team of each centre. Procedural success and major periprocedural complications were defined according to the VARC-2 criteria. 16 
Evaluation of the renal function
Measurements of creatinine levels were systematically obtained within the week prior to the procedure. 
Follow-up
Clinical follow-up was carried out at 30 days, 12 months, and yearly thereafter. The median follow-up was of 15 (5-29) months and no patient was lost to follow-up. All clinical events during the follow-up period were defined according to the VARC-2 criteria. 16 The patients underwent a
Doppler echocardiographic examination at baseline before the intervention, at hospital discharge, at 12-month follow-up, and yearly thereafter. The NYHA class was evaluated before the procedure and at each point time during the follow-up period.
Statistical analysis
Continuous variables are presented as mean (standard deviation) or median (25th-75th inter-quartile range) depending on variable distribution. Group comparisons were tested for differences with one-way analysis of variance for continuous variables, and the Pearson's bivariate and x 2 tests for categorical variables. Comparisons of clinical outcomes between groups were adjusted for baseline differences between groups using a logistic regression analysis that included variables with P-value ,0.05 in the univariate analysis, and CKD stage 1 -2 was the referent for comparison with the other groups. Baseline and procedural variables exhibiting a P-value ,0.05 in the univariate analysis were included in a logistic regression analysis or in a Cox multivariable analysis to determine the predictive factors of 30-day and cumulative late mortality in the whole population and in the advanced CKD groups. Changes in valve haemodynamics over time between groups were compared using a repeated-measures model with interactions. Further comparisons were performed using the Tukey's technique. Survival curves were presented as Kaplan -Meier curves, and the log-rank test was used for comparison between groups. The results were considered significant with P-values ,0.05. All analyses were conducted using the SAS statistical package version 9.2 (SAS Institute, Inc., Cary, NC, USA).
Results
Of Values are expressed as mean (SD), median (IQR), or n (%). eGFR, estimated glomerular filtration rate; CABG, coronary artery bypass graft; CKD, chronic kidney disease; STS-PROM, Society of Thoracic Surgeons predicted risk of mortality; LVEF, left ventricular ejection fraction.
Thirty-day and late outcomes
Early (30-day) and late outcomes following TAVI grouped according to CKD severity are shown in Table 2 . The presence of CKD stage 4 was associated with a higher rate of 30-day stroke (P ¼ 0.010) and major/life-threatening bleeding (P ¼ 0.001). Patients with advanced CKD (stage 4 and 5) had a trend towards a higher 30-day mortality (P ¼ 0.089). Late outcomes showed that advanced CKD groups had a higher rate of all-cause mortality (P , 0.001), mainly due to an increase in cardiovascular mortality in the CKD stage 4 group, and non-cardiovascular mortality in the CKD stage 5 group (P , 0.01 for all). Non-cardiovascular mortality was secondary mainly to kidney disease progression (P , 0.001) and bleeding events (P ¼ 0.004). The aetiology of bleeding events according to CKD severity is shown in Supplementary material online, Table S1 . A total of 12 patients in the advanced CKD group died because of terminal kidney failure, and in 5 of them dialysis therapy was not indicated due to co-morbidities and advanced age. The Kaplan -Meier survival curves according to the severity of CKD are shown in Figure 1A -C ). Uni-and multivariable analyses to evaluate the predictors of 30-day major/life-threatening bleeding, 30-day mortality, and cumulative late mortality are shown in Tables 3 and 4 Values are expressed as n (%) or median (IQR). a n ¼ 1895 patients (excluding patients with previous dialysis).
55-175), P ¼ 0.639]. There was an association between the severity of CKD pre-procedure and the occurrence of AKI and need for dialysis following TAVI (P ¼ 0.001 for both), Valve haemodynamics and functional status changes following transcatheter aortic valve implantation
Echocardiographic data at 1-year follow-up were available in 1038 patients (79% of the patients at risk). Changes in valve haemodynamics following TAVI, according to CKD severity are shown in Figure 2 . There were no differences in valve haemodynamics (mean transvalvular gradient, valve area) over time across the CKD groups (P . 0.30 for both). Changes in functional class following TAVI, according to the severity of CKD are shown in Figure 3A and B). Similar improvements in NYHA class were observed following TAVI among the different groups of CKD (P ¼ 0.126), and no significant differences between groups (P ¼ 0.693) were observed at 1-year follow-up.
Prognostic factors in advanced chronic kidney disease patients
The uni-and multivariable analyses evaluating the factors associated with poorer outcomes among patients with advanced CKD (stage 4 and 5) are shown in Table 5 . In the multivariable analysis, a history of atrial fibrillation (AF) (HR: 2.29, 95% CI: 1.47-3.58, P ¼ 0.001), and dialysis therapy (HR: 1.86, 95% CI: 1.17-2.97, P ¼ 0.009) determined a higher risk of cumulative late death. Kaplan -Meier survival curves according to the presence of chronic atrial fibrillation, dialysis or both are shown in Figure 4 . Patients with advanced CKD in dialysis and a history of AF undergoing TAVI had a mortality rate of 70.8% at 1-year follow-up (vs. 20.1% in the absence of these two risk factors; P , 0.001) and of 100% at 2-year follow-up (vs. 28.4% in the absence of these two factors, P , 0.001).
Discussion
In patients undergoing TAVI, the presence of advanced CKD (stage 4 and 5) was an independent predictor of major/life-threatening bleeding and death within the 30 days after the TAVI procedure. Also, patients with advanced CKD (stage 4 and 5) were at higher risk of mortality after a median follow-up of 15 months, and this was related to an increased risk of overall, cardiovascular and noncardiovascular mortality, especially secondary to kidney disease progression and bleeding complications. The presence of advanced CKD was not associated with any significant deterioration in valve haemodynamics at 1-year follow-up, and those patients with advanced CKD experienced improvements in functional status similar to those of the rest of the TAVI population. Among advanced CKD patients, the presence of pre-existing AF or dialysis determined a higher risk of death following TAVI. Only 30% of the patients with both factors (dialysis therapy and pre-existing AF) were alive at 1-year follow-up and none at 2 years.
Advanced chronic kidney disease as a predictor of poorer outcomes
The presence of CKD has been shown to be an important factor of poorer outcomes in patients undergoing TAVI. 8 More recently, some studies have shown that the prognostic value of CKD is associated with its severity, with those patients with severe CKD exhibiting the highest risk of death acutely and at mid-term follow-up.
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Consistent with these data, in the present study advanced CKD (eGFR,30 mL/min/1.73 m 2 or dialysis) was associated with an increased risk of death at 30-days and after a median follow-up of 15 months following TAVI. Also, advanced CKD led to increased risk of both cardiovascular and non-cardiovascular death. Chronic kidney disease has been associated with increased cardiovascular mortality through an accelerated progression of coronary artery disease and coronary events, exacerbation of congestive heart failure and an increased risk of sudden death. 2, 20, 21 Patients with aortic stenosis undergoing TAVI exhibit a high prevalence of coronary artery disease, systolic and diastolic heart failure and conduction disturbances, 8 and the presence of CKD may therefore worsen clinical outcomes by further affecting all these cardiovascular abnormalities. The rate of 20% of AKI following TAVI and the fact that CKD stage 4 was associated with a higher risk of AKI and CKD progression leading to increase mortality is consistent with previous reports. 22, 23 Also, CKD stage 4 and 5 was associated with a higher risk of peri-procedural and follow-up bleeding events. Prior studies have also reported a higher incidence of acute and late life-threatening bleeding events among patients with advanced CKD undergoing TAVI. 10, 12 Advanced CKD has been associated with platelet dysfunction and haemostatic abnormalities consistent with a hypercoagulable state leading to a higher risk for haemorrhagic events, especially in those patients on dual antiplatelet or warfarin therapy. 24 -27 The difficult equilibrium between thrombotic and haemorrhagic events and the implications for antithrombotic treatment have been well recognized in TAVI patients. 28 The present study showing that the major role of bleeding events in the poorer outcomes of such patients strongly suggests the advisability of avoiding antithrombotic overtreatment and the questionability of using systematic dual antiplatelet therapy in this challenging group.
Advanced chronic kidney disease and transcatheter aortic valve implantation: identifying those patients at highest risk
The poorer outcomes associated with advanced CKD in patients undergoing TAVI may raise the question of whether or not these high-risk patients do indeed benefit from this procedure, and which patients would be at highest risk for poorer outcome. No data exist to date regarding risk stratification among these patients and, to the best of our knowledge, this is the first study to specifically evaluate the factors associated with poorer outcomes among patients with advanced CKD. Importantly, a history of AF and dialysis therapy were the factors determining worse outcomes in such patients, with those patients with the combination of these two factors exhibiting a dismal prognosis following successful TAVI. On the other hand, patients with advanced CKD and neither of these factors presented similar outcomes to those of the rest of the study population. The presence of renal failure requiring dialysis is a well-known prognostic factor among CKD patients, especially in those with cardiovascular conditions and in those undergoing cardiac surgery.
2,5 -7
Dumonteil et al. 10 found an increased risk for mortality among 33 dialysis patients undergoing TAVI, with a mortality rate close to 30% at 1-year follow-up. On the other hand, Rau et al. 29 evaluated 10 dialysis patients who underwent TAVI, showing outcomes at 6-month follow-up similar to those of 116 non-dialysis patients. The present study, which included one of the largest series of dialysis patients undergoing TAVI to date, showed a slightly higher mortality at 1-year follow-up among dialysis patients, and a higher increase in mortality after the first year.
In the absence of aortic stenosis, advanced CKD has been associated with a higher incidence of AF, which in turn translates into much higher rates of mortality at mid-term follow-up. 2,30 -35 The present study also showed a higher rate of pre-existing AF among TAVI candidates with CKD stage 4, and AF was indeed found to be the most important prognostic factor in this group of patients. The mortality rate in patients with advanced CKD and AF was as high as 41 and 56% at 1-and 2-year follow-up, respectively. In those patients with AF and dialysis, the mortality rate was as high as 71% at 1-year follow-up, and all patients with these two factors had died in ,2 years following the TAVI procedure. Pre-existing AF has been recognized as an important prognostic factor in TAVI, and this has been related to an increase in decompensated heart failure, and thrombo-embolic and bleeding events. 36 This study showed that pre-existing AF is the most important prognostic factor in patients with advanced CKD, and this factor identified a group of TAVI candidates with an ominous prognosis when associated with chronic dialysis. These results suggest that elderly patient with aortic stenosis on dialysis therapy and AF should be proposed for TAVI with extreme caution and after thorough evaluation by the heart team. If finally accepted for this procedure, a very close follow-up and probably an adjustment in antithrombotic therapy should be applied in order to reduce bleeding events, which are one of the main drivers of periprocedural and late mortality in these patients. In fact, the use of warfarin in patients with AF and dialysis has been controversial, with some studies showing an excess of major bleeding complications without a clear reduction in thromboembolic events in this group of patients. 37, 38 appendage closure should probably be considered in this high-risk group of patients.
Advanced chronic kidney disease, functional status, and valve haemodynamics
The presence of advanced CKD, and particularly the need for dialysis, has been associated with a more rapid deterioration of valve haemodynamics and the use of biological (vs. mechanical) aortic bioprostheses in this setting has been controversial. 7,13 -15 In the present study, the presence of advanced CKD, including patients on dialysis, was not associated with a more rapid deterioration of valve haemodynamics within the months following the procedure. Future studies will be needed to confirm these data at longer term follow-up. The presence of advanced CKD has been associated with a decrease in functional status and quality of life. 1 However, the present study showed that in those patients who survived the TAVI procedure and were alive at 1-year follow-up, the NYHA class improved significantly in a similar manner to the rest of the study population. This highlights the fact that the procedure was not futile in a significant proportion of patients, and increases the clinical relevance of better identifying those patients with advanced CKD who are likely to survive following a TAVI procedure. However, future studies with more Advanced chronic kidney disease in patients undergoing TAVI objective and reliable functional tests and quality of life data will be needed to further determine the futility of TAVI in patients with advanced CKD.
Study limitations
While the calculation of eGFR values using the MDRD equation has been largely validated and its superiority with respect to simple serum creatinine values for evaluating renal function is well established, its use in elderly patients has some limitations mainly due to the significant decline in muscle mass in this population. 39 Several differences in baseline characteristic were present across the groups. Despite adjustment for differences between groups, this may not control for all confounding factors and some bias in the final results cannot be ruled out. The fact that patients in the CKD stage 5 group were significantly younger than the other groups may be due to a selection bias related to anticipated poorer outcomes in older patients on regular dialysis treatment. Data on administration of contrast media (such as preoperative computed tomography or percutaneous coronary intervention) within the same hospital stay were not available. There was no independent event adjudication committee for this study; and while this might have been less relevant for the outcome of mortality (yes/no), it is a limitation when establishing the causes of death, especially during the follow-up period. While clinical data were prospectively collected in each participating centre, data analyses were performed retrospectively and there was no prespecified case report form designated for this study. Finally, no data on the type and number of antithrombotic drugs and changes in renal function over time were available.
In conclusion, advanced CKD in patients undergoing TAVI seems to determine a higher risk for early and mid-term cardiovascular and non-cardiovascular mortality. The occurrence of severe bleeding events played an important role in early and late deadly events, and the use of antithrombotic therapy overtreatment, especially dual antiplatelet therapy and/or the combination of warfarin with antiplatelet agents, should probably be re-evaluated in such patients. Among advanced CKD patients, those with either AF or dialysis therapy were at the highest risk, and in particular the combination of these two factors led to an unacceptable mortality rate within the months following the TAVI procedure. These data may help to improve the clinical decision-making process in this challenging group of patients.
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